comparison of three adjuvant chemotherapy regimes using an extended log-logistic model in women with operable breast cancer

Asian Pacific Journal of Cancer Prevention

Volumn 11, Issue 2, 2010, Pages 353-358

  Faradmal, Javad ^a   Kazemnejad, Anoshirvan ^a   Khodabakhshi, Reza ^b   Gohari, Mahmood Reza ^c   Hajizadeh, Ebrahim ^a  

^a TARBIAT MODARES UNIVERSITY   (Iran)

^b Fayyazbakhsh Hospital   (Iran)

^c IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Adjuvant chemotherapy; Breast neoplasms; Disease free survival; Survival analysis

Indexed keywords

EID: 78650689459     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. American Joint Committee on Cancer: AJCC 2002. Cancer Staging Manual, New York, Springer.
2. Alexander FE, Anderson TJ, Brown, et al. (1999). 14 years of follow-up from the Edinburgh randomised trial of breastcancer screening. Lancet, 353, 1903-8.
3. Anderson WF, Chen BE, Jatoi I, et al (2006). Effect of estrogen receptor expression and histopathology on annual hazard rates of death from breast cancer. Breast Cancer Res Treat, 100, 121-6.
4. Bakhtyari A, Hajyan K. (2007). Rate of 5-year disease-free survival in breast cancer patients referred to Shahid-Rajaeee-Babolsar hospital. J school of public health and institute of public research, 5, 53-9 (Persian).
5. Bonadonna G, Brusamolino E, Valagussa P, et al. (1976). Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med, 294, 405-10.
6. Browne WJ. (1998). Applying MCMC Methods to Multi-level Models. PhD thesis, university of Bath.
7. Browne, WJ. (2006). MCMC algorithms for constrained variance matrices. Comput Stat Data Anal, 50, 1655-77.
8. Cancer office of center for disease control and prevention (2007). Iranian annual national cancer registration report 2005-2006. Tehran: Ministry of Health and Medical Education of IR Iran, Office of Deputy Minister for Health. Available from: http://www.emro.who.int/ncd/pdf/cancer_registry_iran.pdf.
9. Cocconi G, Salvagni S, Passalacqua R, et al. (2004). Design and development of new combinations of the cmf agents with taxanes (paclitaxel or docetaxel) in advanced breast cancer: a feasibility study. Tumori, 90, 280-4.
10. Dignam JJ, Dukic V, Anderson SJ, et al. (2009). Hazard of recurrence and adjuvant treatment effects over time in lymph node-negative breast cancer. Breast Cancer Res Treat, 116, 595-602.
11. Early Breast Cancer Trialist Collaborative Group (1992). Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet, 339, 1-15.
12. Fazl-Ali Zadeh A, Hatami E. (2004). Study of impact of reducing radiotherapy duration after mastectomy on rate of recurrence in breast cancer patients. Pajohandeh, 9, 209-14 (Persian).
13. Francis P, Crown J, Di Leo A, et al. (2008). Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial. J Natl Cancer Inst, 100, 121-33.
14. Harirchi I, Karbakhsh M, Kashefi A, et al. (2004). Breast cancer in Iran: Results of multicenter study. Asian Pac J Cancer Prev, 5, 24-7.
15. Hayes DF. (2009). Is there a standard type and duration of adjuvant chemotherapy for early stage breast cancer? Breast, 18 (Suppl 3), S131-4.
16. Hayes DF, Thor AD, Dressler LG, et al. (2007). HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med, 357, 1496-506.
17. Hess KR, Pusztai L, Buzdar AU, et al. (2003). Estrogen receptors and distinct patterns of breast cancer relapse. Breast Cancer Res Treat, 78, 105-18.
18. Kadivar M, Bozorgmehr N. (2007). Study of cytologic grading of samples obtained from breast carcinoma cases referred to Milad and Rasoul-e-Akram hospital between 2004 and 2005. J Iran university of medical sciences, 54, 129-38 (Persian).
19. Kalbfleisch JD, Prentice RL. (2002). The statistical analysis of failure time data. Johan Wiley and Sons, New Jersey.
20. Klein JP, Moeschberger ML. (1997). Survival analysis: Techniques for censored and truncated data. Springer, New York.
21. Kleinbaum DG, Klein M. (2005). Survival analysis: A self learning text. Springer, New York.
22. Lamyian M, Hydarnia A, Ahmadi F, et al. (2007). Barriers to and factors facilitating breast cancer screening among Iranian women: A qualitative study. East Mediterr Health J, 13, 1160-9.
23. Le Doussal V, Tubiana-Hulin M, Freidmans S, et al. (1989). Prognostic value of histologic grade nuclear components of Scarff-Bloom-Richardson (SBR). An improved score modification based on a multivariate analysis of 1262 invasive ductal breast carcinomas. Cancer, 64, 1914-21.
24. Mamounas EP, Bryant J, Lembersky B,et al. (2005). Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol, 23, 3686-96.
25. Martin M, Villar A, Sole-Calvo A, et al. (2003). Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a study by the GEICAM group. Annal Oncol, 14, 833-42.
26. De Laurentiis M, Cancello G, D'Agostino D, et al. (2008). Taxane-based combinations as adjuvant chemotherapy of early breast cancer: A meta-analysis of randomized trials. J Clin Oncol, 26, 44-53.
27. Montemurro F, Aglietta M. (2009). Hormone receptor-positive early breast cancer: Controversies in the use of adjuvant chemotherapy. Endocr Relat Cancer, 16, 1091-102.
28. Nyström L, Andersson I, Bjurstam N, et al. (2002). Long-term effects of mammography screening: updated overview of the Swedish randomised trials. Lancet, 359, 909-19.
29. Royston P. (2001). The lognormal distribution as a model for survival time in cancer, with an emphasis on prognostic factors. Stat Neerl, 55, 89-104.
30. Sadjadi A, Nouraie M, Ghorbani A, et al. (2009). Epidemiology of breast cancer in the Islamic Republic of Iran: first results from a population-based cancer registry. East Mediterr Health J, 15, 1426-31.
31. Saphner T, Tormey D, Gray R. (1996). Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol, 14, 2738-46.
32. Shen Y, Yang Y, Inoue LY, et al. (2005). Role of detection method in predicting breast cancer survival: Analysis of randomized screening trials. J Natl Cancer Inst, 97, 1195-203.
33. Soerjomataram I, Louwman MW, Ribot JG, et al. (2008). An overview of prognostic factors for long-term survivors of breast cancer. Breast Cancer Res Treat, 107, 309-30.
34. Weiss RB, Woolf SH, Demakos E, et al. (2003). Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based adjuvant chemotherapy: A study by the Cancer and Leukemia Group B. J Clin Oncol, 21, 1825-35.